SanFran,

This recent news release sums it up. Regarding the clinical trial, there are no concrete details. Similar to the renal and Fabrys disease programs that were launched, but after being listed in ClinicalTrials.gov for over 3 years but never recruiting, I worry that another "planned" trial will just stay as that.....planned with no action.

"An additional step will be to proceed with an open-label study to assess the safety and efficacy of a clinical course of oral apabetalone in hospitalized subjects with 2019-nCoV infection on top of standard of care compared to standard of care alone. Endpoints will include clinical progression, an evaluation of viral levels via nasal and pharyngeal swabs, as well as the effect of apabetalone on key virus-related biomarkers including ACE2 and others within the renin-angiotensin system, as well as an inflammatory panel of markers including IL6, IL8, CRP, etc. in hospitalized subjects with 2019-nCoV infection."